Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06508320 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
A Phase 2 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 2
- Development phase
- 932
- Enrollment target
NCT06508320: Completed Phase 2 study, sponsored by ModernaTX.
NCT06508320 is a Phase 2 study that has completed, run by ModernaTX. The registered enrollment target is 932 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (601% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06508320, a Phase 2 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 932 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.
Interventions
- BIOLOGICAL mRNA-1083
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 932 participants |
| Start Date | 2024-07-15 |
| Est. Completion | 2025-09-25 |
| Phase | Phase 2 |
What the finished NCT06508320 record still lists
NCT06508320 is an interventional study that assigns participants to a tested intervention. The registered 932 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (601% higher).
The record links to 0 conditions, and to 1 intervention - of which mRNA-1083 is the first listed.
NCT06508320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06508320 about?
NCT06508320 is a clinical study titled "A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)". The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.
What is the current status of trial NCT06508320?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 932 participants. The study started on 2024-07-15. Estimated completion is 2025-09-25.
What interventions are being tested in trial NCT06508320?
The interventions under investigation include: mRNA-1083 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06508320?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06508320's enrollment target sits among peer trials
932 29th of 2000 higher than 1,972 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04626635 · 933 participants · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- NCT06932029 · 930 participants · NA
SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases
- NCT07235085 · 930 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI